Lyell Immunopharma, Inc.
Close on Oct 19, 2026
- Market cap
- $205.60M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | After market close | $4.00K | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | After market close | $2.00K | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 12, 2026 | After market close | $6.00K | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | After market close | $15.00K | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | After market close | $7.00K | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 11, 2025 | After market close | $11.00K | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 6, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 28, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Mar 11, 2025, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| net cash use | 2025 | $175.00M to $185.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Lyell Immunopharma filed with the SEC
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in
Other events · EX-99.1 to Form 8-K
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026
Results of operations · EX-99.1 to Form 8-K
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026
Results of operations · EX-99.1 to Form 8-K
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results
Results of operations · EX-99.1 to Form 8-K
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025
Results of operations · EX-99.1 to Form 8-K
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025
Results of operations · EX-99.1 to Form 8-K
Lyell Immunopharma Announces up to $100 Million Equity Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025
Results of operations · EX-99.1 to Form 8-K
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024
Results of operations · EX-99.1 to Form 8-K
Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial
Other events · EX-99.1 to Form 8-K
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024
Results of operations · EX-99.1 to Form 8-K
Lyell Immunopharma Completes Acquisition of ImmPACT Bio
Material agreement · Acquisition or disposition completed · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024
Results of operations · EX-99.1 to Form 8-K
Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
of LYL797, an Enhanced ROR1-targeted CAR-T Cell Product Candidate June 26, 2024 1
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
Results of operations · EX-99.1 to Form 8-K
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
Results of operations · EX-99.1 to Form 8-K
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
Results of operations · EX-99.1 to Form 8-K
“anticipates,” “expects,” plans“,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “could,” “might,” “will,”
Regulation FD disclosure · EX-99.1 to Form 8-K
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023
Results of operations · EX-99.1 to Form 8-K
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023
Results of operations · EX-99.1 to Form 8-K
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
Results of operations · EX-99.1 to Form 8-K
Lyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel
Regulation FD disclosure · EX-99.1 to Form 8-K
Lyell Immunopharma Reports Second Quarter Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Lyell Immunopharma Reports First Quarter Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Lyell Immunopharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Lyell Immunopharma Announces cGMP Qualification of LyFE
Material agreement · Other events · EX-99.1 to Form 8-K
Lyell Immunopharma Announces FDA Clearance of its IND for LYL797, a CAR T-Cell
Material agreement · Other events · EX-99.2 to Form 8-K
Lyell Immunopharma Reports Third Quarter 2021 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K